PALUMBO, Antonio
 Distribuzione geografica
Continente #
NA - Nord America 17335
EU - Europa 11356
AS - Asia 8253
SA - Sud America 494
OC - Oceania 316
AF - Africa 133
Continente sconosciuto - Info sul continente non disponibili 35
Totale 37922
Nazione #
US - Stati Uniti d'America 16625
CN - Cina 4656
IT - Italia 2536
FR - Francia 1364
DE - Germania 1322
JP - Giappone 1174
SE - Svezia 1031
GB - Regno Unito 1007
KR - Corea 947
UA - Ucraina 767
FI - Finlandia 733
CA - Canada 567
PL - Polonia 542
AT - Austria 462
ES - Italia 399
VN - Vietnam 381
IN - India 331
AU - Australia 279
BR - Brasile 258
NL - Olanda 207
CH - Svizzera 171
RU - Federazione Russa 170
TR - Turchia 153
MX - Messico 118
GR - Grecia 117
CO - Colombia 110
TW - Taiwan 109
BE - Belgio 104
HK - Hong Kong 94
SN - Senegal 70
SG - Singapore 68
IL - Israele 65
PT - Portogallo 57
DK - Danimarca 56
RO - Romania 55
TH - Thailandia 52
AR - Argentina 50
HU - Ungheria 48
IE - Irlanda 44
SA - Arabia Saudita 44
NZ - Nuova Zelanda 37
CL - Cile 35
CZ - Repubblica Ceca 34
EU - Europa 32
ID - Indonesia 32
NO - Norvegia 31
PK - Pakistan 31
ZA - Sudafrica 23
PE - Perù 21
HR - Croazia 19
BY - Bielorussia 18
IR - Iran 18
PH - Filippine 18
UZ - Uzbekistan 17
MY - Malesia 16
EG - Egitto 14
BG - Bulgaria 13
DZ - Algeria 10
UY - Uruguay 10
JO - Giordania 9
EC - Ecuador 8
EE - Estonia 8
SK - Slovacchia (Repubblica Slovacca) 8
CU - Cuba 7
MA - Marocco 6
SI - Slovenia 6
CR - Costa Rica 5
LB - Libano 5
LK - Sri Lanka 5
LT - Lituania 5
PA - Panama 5
AL - Albania 4
QA - Qatar 4
CY - Cipro 3
GE - Georgia 3
IQ - Iraq 3
LU - Lussemburgo 3
LV - Lettonia 3
MK - Macedonia 3
AD - Andorra 2
AE - Emirati Arabi Uniti 2
AP - ???statistics.table.value.countryCode.AP??? 2
BD - Bangladesh 2
GT - Guatemala 2
IS - Islanda 2
KE - Kenya 2
KW - Kuwait 2
KY - Cayman, isole 2
KZ - Kazakistan 2
MU - Mauritius 2
NP - Nepal 2
OM - Oman 2
RS - Serbia 2
SV - El Salvador 2
TN - Tunisia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
ET - Etiopia 1
Totale 37912
Città #
Beijing 2630
Fairfield 1298
Houston 1040
Ashburn 920
Wilmington 827
Villeurbanne 801
Redwood City 669
Woodbridge 657
Princeton 620
Ann Arbor 617
Jacksonville 588
Medford 573
Seattle 554
Cambridge 548
Torino 501
Dearborn 441
Tokyo 441
Duncan 440
Warsaw 430
Chandler 420
Vienna 409
Pisa 349
Hangzhou 333
Dong Ket 250
Florence 229
Fremont 227
Shanghai 220
San Mateo 201
Boston 188
Toronto 146
Guangzhou 143
Nanjing 143
Milan 142
Raritan 130
Ottawa 127
Norwalk 119
Turin 110
Nyköping 108
San Diego 97
London 94
New York 93
Newbury Park 91
Rochester 88
Zhengzhou 85
Taipei 83
Phoenix 79
Saint Petersburg 73
Munich 70
Wuhan 67
Rome 65
Seoul 62
Falls Church 60
Central District 59
Düsseldorf 57
Hefei 57
Xian 55
Chengdu 51
Mcallen 50
Changsha 49
Jinan 49
Singapore 49
Sydney 49
Nanchang 47
San Francisco 47
São Paulo 46
Chicago 45
Paris 43
Hebei 41
Tianjin 41
Madrid 40
Mountain View 38
Bologna 37
Changchun 37
Brussels 34
Durham 34
Flushing 34
Osaka 34
Istanbul 33
Santiago 32
Silver Spring 32
Bogotá 31
Barcelona 30
Verona 30
Athens 29
Atlanta 29
Budapest 29
Fuzhou 29
Hyderabad 29
Columbus 28
Polska 28
Kunming 27
Montréal 27
Québec 27
Richmond 27
Brooklyn 26
Novara 26
Oxford 26
Portland 26
Saint Louis 25
Charlotte 24
Totale 21469
Nome #
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): And randomised, phase 3, open-label, multicentre study 6096
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: A randomised, multicentre, phase 3 trial 1408
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study 1173
Second primary malignancies in multiple myeloma: an overview and IMWG consensus 1134
A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma 686
Plasma cell leukemia: update on biology and therapy 520
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma 447
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. 432
Optimizing treatment for elderly patients with newly diagnosed multiple myeloma: A personalized approach 422
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma 419
Bendamustine for the treatment of multiple myeloma in first-line and relapsedrefractory settings: A review of clinical trial data 408
Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma 401
Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting) 384
MET/HGF pathway in multiple myeloma: From diagnosis to targeted therapy? 322
How i treat fragile myeloma patients 317
IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies 307
The role of pre-transplant induction regimens and autologous stem cell transplantation in the era of novel targeted agents 281
Autologous Transplantation and Maintenance Therapy in Multiple Myeloma 279
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. 265
European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications 221
Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma 210
Role of consolidation/maintenance therapy in multiple myeloma. 206
Novel investigational drugs active as single agents in multiple myeloma 202
International Myeloma Workshop Consensus Panel 1. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1 194
Have drug combinations supplanted stem cell transplantation in myeloma? 176
Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. 175
MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients. 173
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results 169
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma 168
Prospective molecular monitoring of minimal residual disease after nonmyeloablative allografting in newly diagnosed multiple myeloma 165
Management of older adults with multiple myeloma. 164
Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma 162
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group 161
Sustained disease control in transplant-ineligible patients: the role of continuous therapy. 161
International Myeloma Working Group. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. 159
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis 156
Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: Results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study 155
Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma 153
Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO) 152
Role of magnetic resonance imaging in the management of patients with multiple myeloma: A consensus statement 152
Treatment of newly diagnosed elderly multiple myeloma 151
Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide 151
European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma. 149
Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma 148
Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns 146
Immunotherapy: the next step in the treatment of myeloma 143
Bortezomib (VEL) Based Regimens in Multiple Myeloma (MM) Patients with Renal Impairment (RI): A Preliminary Retrospective Italian Multicenter Study 142
Initial treatment of nontransplant patients with multiple myeloma. 139
MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis 138
Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials 137
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis 132
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis 131
Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis 130
New pharmacotherapy options for multiple myeloma 124
Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance. 117
Does low-molecular-weight heparin influence the antimyeloma effects of thalidomide? A retrospective analysis of data from the GIMEMA, nordic and turkish myeloma study groups 114
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. 111
Efficacy and safety of once weekly bortezomib in multiple myeloma patients. 111
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. 109
Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial 109
Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: A meta-analysis 108
A Simple Score, Based On Geriatric Assessment, Improves Prediction of Survival, and Risk Of Serious Adverse Events In Elderly Newly Diagnosed Multiple Myeloma Patients 105
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the international myeloma working group 105
Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies 101
ACHIEVEMENT OF COMPLETE REMISSION IS A STRONG PROGNOSTIC FACTOR IN 895 ELDERLY MYELOMA PATIENTS TREATED WITH MELPHALAN-PREDNISONE BASED-REGIMENS: RESULTS OF 3 MULTICENTER ITALIAN TRIALS 100
Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: Use of “progression-free survival 2” as a clinical trial end-point 97
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. 96
Balancing act for elderly myeloma. 95
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. 95
Hematopoietic stem and progenitor cell composition in peripheral blood and in mobilized CD34+ cells harvests. 94
The impact of response on bone-directed therapy in patients with multiple myeloma 94
Global myeloma research clusters, output, and citations: a bibliometric mapping and clustering analysis 94
High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma 93
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial 93
Early response predicts myeloma outcome. 92
EXPRESSION OF MET MRNA AS PROGNOSTIC MARKER IN MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL DRUGS 91
Continuous lenalidomide treatment for newly diagnosed multiple myeloma 91
High-risk myeloma: when to transplant-or not. 91
Is there a role for allografting in myeloma ?: an update of a comparative study 91
Management of older patients with multiple myeloma 90
Autologous Transplantation in Elderly Multiple Myeloma Patients: Is the Procedure Cost Effective? 89
Lenalidomide in the treatment of lymphoproliferative disorders and multiple myeloma. 88
Treatment of newly diagnosed myeloma 88
High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma 87
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: A pooled analysis 87
Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with non-intensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. 86
Characteristics of the Immunoglobulin Heavy Chain (IgH) Rearrangement in Multiple Myeloma (MM): An Analysis On 308 Cases 85
Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias 85
Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial. 85
High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib. 85
High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. 85
A PROSPECTIVE RANDOMIZED TRIAL OF BORTEZOMIB-MELPHALANPREDNISONE-THALIDOMIDE FOLLOWED BY CONTINUOUS BORTEZOMIB-THALIDOMIDE FOR INITIAL THERAPY OF MULTIPLE MYELOMA:EFFECT OF AGE AND CO-MORBIDITIES 85
Proteasome inhibitors in multiple myeloma: ten years later 83
Maintenance Therapy for Multiple Myeloma. 83
Modificazioni dell'attivita' fibrinolitica di cellule di leucemia umana della linea HL60 in risposta ad agenti promuoventi la differenziazione. 83
Management of treatment-emergent peripheral neuropathy in multiple myeloma. 83
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens 82
New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). 81
Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma 80
Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo 80
Totale 25573
Categoria #
all - tutte 48023
article - articoli 0
book - libri 0
conference - conferenze 6766
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 54789


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/20185298 0000 0296 3401011 18761125333317
2018/20195412 308328434335 352290 296641 3294161170513
2019/20207158 397456485988 560831 807529 787512462344
2020/20217020 569378532407 619544 615509 701637715794
2021/20227108 390381368619 387355 915464 3645969251344
2022/20231846 817572294163 00 00 0000
Totale 39707